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Bovine herpesvirus-1 (BHV-1), an alphaherpesvirus, 15 is one of the most ubiquitous and important pathogens of cattle. Like other members of the alphaherpesvirus group, 13 BHV-1 grows rapidly in cell cultures, infects a wide range of cell types, and establishes latent infection in neurons of sensory and autonomic nerve ganglia. 2, 12 The BHV-1 infection causes respiratory and reproductive tract diseases. 21 Cattle infected with BHV-1 exhibit clinical immunosuppression. 3, 9 Animals with acute BHV-1 infection often develop secondary infection with Manheimmia haemolytica. 3 Immune suppression has also been seen in cattle vaccinated with modified live BHV-1 vaccine, as these animals have a reduced antibody response to a commercial M. haemolytica leukotoxin vaccine. 9 Following acute infection, BHV-1 antigen and DNA have been detected in spleen, prescapular lymph nodes, and peripheral blood mononuclear cells (PBMCs) through day 19 postinfection. 1 Other studies 18 have demonstrated BHV-1 antigen in pharyngeal, cervical, retropharyngeal and inguinal lymph nodes, and tonsil 7 days postinfection. They also demonstrated the presence of BHV-1 DNA and antigen in CD4 ϩ but not CD ϩ 8 T cells in the lymph nodes and PBMCs. Recently, BHV-1 latency and reactivation has been demonstrated in tonsil 60 days postinfection. 19 The BHV-1 has also been detected in PBMCs of cattle vaccinated with a live BHV-1 gE-negative vaccine 4-5 months postvaccination using PCR. 7 In this study, BHV-1 glycoprotein D (gD) antigen and DNA were detected in PBMCs from calves 6 and 8 months after BHV-1 infection.
Five yearling beef calves (700-900 lbs) were used in this experiment. These calves were part of a vaccination-duration study (9 animals were in the original study). The other 4 animals were sold 4 months after the challenge. Prior to vaccination, the calves were seronegative (Ͻ2) by serum neutralization to BHV-1, bovine viral diarrhea virus (BVDV) types 1 and 2, and bovine respiratory syncytial virus. The animals were also PCR negative for BHV-1 and BVDV. The vaccinates and control animals were grouped together but kept in strict isolation throughout the vaccination, challenge, and postchallenge period. The vaccinated animals were given 2 doses of a commercial inactivated vaccine a containing BHV-1, 1 month apart, with the last dose given 8 months before challenge. All animals were challenged intranasally with 10 7 tissue culture infectious dose 50 (TCID 50 ) BHV-1 (Cooper strain, ATCC). Following challenge, BHV-1 virus was recovered from all calves. The vaccinated calves shed virus from day 1 to day 6, while the control calves shed virus day 1 through day 8 and the virus titers were consistently higher in the control group (2-3 log 10). There was no difference in clinical signs between control and vacci- (Table 1) . Following challenge, the control calves were all seropositive by 12 days (data not shown). These calves reached an average BHV-1 SN titer of 43 by day 33, 32 by day 68, and 68 by day 89 ( Table 1 ). The 2 vaccinated calves developed BHV-1 SN titers 1 month following vaccination. Prior to challenge (8 months after the second vaccination), only calf 189 had an SN titer ( Table 1 ). The vaccinated calves had a peak titer of 2,048 two weeks following challenge (data not shown). These calves 1 BHV-1 SN titers declined to 768 by day 33, 512 by day 68, and 384 by day 89 (Table 1) . No additional serology samples were taken.
The PBMCs from control calf 201 were isolated at 6 months for use in an in vitro BHV-1 PBMC assay. However, on immunofluorescence testing, the PBMCs were positive for gD expression. The 4 remaining calves from the trial were also screened for BHV-1. Blood was collected and PBMCs were isolated by gradient separation. b,8 PBMCs were centrifuged onto slides using a cytocentrifuge, air dried, and fixed in acetone. Indirect immunofluorescence staining was performed to detect BHV-1 gD in PBMCs. Fixed cells were stained with mouse anti-BHV-1 gD monoclonal antibody (MAb) 1106. f,4,10 The slides were examined under a fluorescent microscope. The other 2 control calves, 267 and 271, also expressed gD, while the 2 vaccinated calves were negative for gD expression ( Table 2) . At 8 months, PBMCs from unvaccinated calves 201, 267, and 271 contained BHV-1 gD-positive stained cells, but the remaining vaccinated calf, 179, was negative for gD expression ( Table 2 ). There were 5-6% positive gD cells at 6 months, compared with 2-3% gD-positive cells at 8 months. Negative control PBMCs were obtained from a seronegative and PCR-negative calf for BHV-1. An in vitro BHV-1-positive control was obtained by infecting BHV-1-negative PBMCs with BHV-1 at multiplicity of infection 5 (results not shown).
Nested PCR was used in this study to detect the presence of BHV-1 DNA. Sample preparation and nested PCR were performed according to previously described methods. 17 Two external primers and 2 internal primers ( Table 3) were used in the amplification of the BHV-1 gD gene. The 2 external primers amplified a 468-bp product and the 2 internal primers amplified a 325-bp fragment of BHV-1 gD gene. The amplified PCR products were analyzed by electrophoresis on 1.5% agarose gels and were visualized by ethidium bromide staining. To assess the sensitivity of the PCR amplification, PBMCs (1 ϫ 10 6 cells) from a BHV-1-seronegative and PCR-negative animal were inoculated with a known number of infectious viruses as determined by TCID 50 . The BHV-1 was 10-fold serially diluted and then added to PBMC. The DNA was extracted from these cells and used in the PCR reaction. With this protocol, amplification of 50 TCID 50 BHV-1 DNA produced a visible PCR 325-bp band (Fig. 1,  lane 6 ), while 5 TCID 50 produced a poorly discernible PCR signal (Fig. 1, lane 7) .
The BHV-1 DNA in PBMCs (1 ϫ 10 6 cells) collected from calves at 8 months postinfection was detected by PCR. Samples from 2 unvaccinated calves (201 and 267) produced a 325-bp PCR fragment (Fig. 2 , lanes 4 and 6, respectively; Table 2 ). One vaccinated calf, 271 (Fig. 2, lane 5 ; Table 2 ), and 1 unvaccinated calf, 179 (Fig. 2, lane 3 ; Table 2 ), did not show any BHV-1-positive signal. The identities of the PCR products were confirmed by southern hybridization. The DNA was transferred from the gel to nylon membranes c and cross-linked to the membranes by ultraviolet illumination. Membranes were treated with prehybridization solution and then hybridized with BHV-1 gD probe radiolabeled with ␣-32 P-ATP by using T4 polynucleotide kinase. d, 14 The membranes were analyzed for radiobinding using an image analysis system e . The positive PCR results were verified as BHV-1 by hybridization ( Fig. 3) .
To isolate virus from PBMC, PBMC preparations were disrupted by freezing and thawing twice. Virus isolation was performed on bovine turbinate cells. The cell lysate was applied to the cells and incubated for 14 days. No infectious Fig. 3 by southern hybridization using the 32 P-labled BHV-1 glycoprotein gD probe to PCR products. virus was recovered from any PBMC specimens at 8 months postinfection ( Table 2) .
In this study, PBMC from calves at 6 and 8 months after challenge were tested for viral antigen, DNA, and infectious virus ( Table 2 ). The BHV-1 DNA was detected by PCR in PBMCs from 2 of the BHV-1-infected control calves, but BHV-1 DNA was not detected from the other unvaccinated control calf or from the only vaccinated calf tested. The BHV-1 gD antigen was found in the 3 unvaccinated calves but not in the vaccinated animals. No infectious virus was detected in PBMC samples from any of these animals. The lack of infectious virus in the PBMCs is not a surprising finding. Analysis of BHV-1-infected CD4 ϩ T cells demonstrated that these cells expressed only the early viral protein gD and not the late protein gC, indicating a productive BHV-1 infection was not efficient. 19 Work in our laboratory with BHV-1-infected adherent bovine monocytes derived from PBMC demonstrated a restriction in BHV-1 viral gene expression in monocytes, with 20% of the cells expressing the early gD gene, compared with 6% of the cells expressing the late gC protein. There was also less than a 10-fold increase in virus progeny over the input virus at the end of a 48-hour BHV-1 growth curve in the adherent bovine monocytes, indicating a restriction of viral replication (unpublished manuscript).
These results suggest the possibility that lymphoid tissues may also function as sites for latency, from which viruses may transfer to other tissues. This is supported by the identification of latent BHV-1 in tonsilar lymphoid tissue 60 days postinfection 19 and the detection of marker BHV-1 vaccine DNA in PBMC 4-5 months postvaccination. 6 The ability of alphaherpersvirus to establish latency is a unique function of their biology. During primary infection, BHV-1 is transported along axons and becomes latent in peripheral ganglia, where it persists for the lifetime of the animal. 2 It has also been demonstrated that BHV-1 has a predilection for lymphoid tissues in the early stage of infection 1, 18 and that bovine peripheral blood lymphocytes, monocytes, and alveolar macrophages were susceptible to BHV-1 infection in vi-tro. 1, 7, 11 Two animal alphaherpesviruses, equine herpesvirus-1 and pseudorabies, also establish latent infection in lymphoid tissues and PBMCs. 5, 16, 20 Whether this latent virus in PBMCs and lymphoid tissue has an immunostimulatory effect that is important for protection or an immunosuppressive effect that compromises the host is still a question needing further investigation. Information on the effect of BHV-1 on PBMCs in latently infected animals will improve our understanding of the pathogenesis of BHV-1. 
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